Recurrent Bell’s Palsy

1974 ◽  
Vol 7 (2) ◽  
pp. 407-409
Author(s):  
W. Hugh Powers
Keyword(s):  
2012 ◽  
Vol 73 (S 02) ◽  
Author(s):  
L. M. Marques ◽  
J. Pimentel ◽  
P. Escada ◽  
G. Neto D'Almeida

Diabetes ◽  
1975 ◽  
Vol 24 (5) ◽  
pp. 449-451 ◽  
Author(s):  
K. Adour ◽  
J. Wingerd ◽  
H. E. Doty

2019 ◽  
Author(s):  
Myung Chul Yoo ◽  
Yunsoo Soh ◽  
Jinmann Chon ◽  
Jong Ha Lee ◽  
Junyang Jung ◽  
...  

Author(s):  
Lodha Sheetal Ganeshlalji

Ardita is one of the Vata Vyadhi. Management of Ardita is same as Vata Vyadhi. It includes Nasya, Murdhnitala, Basti. Karnapurana and Akshitarpana. Akshitarpana is a unique procedure where medicated ghee is retained over the eyes for a specific amount of time. Ardita can be correlated with Bell’s palsy. Symptoms like incomplete closure of eye, watering of eye, deviation of mouth, forehead creases loss, earache, dribbling of saliva, heaviness of face, taste loss, hyperacusis are same. In this study efficacy of Akshitarpan is evaluated in Ardita. Triphala Ghruta is selected to do Akshitarpan. Subjective criteria for assessment are watering of eye, deviation of mouth, forehead creases loss, earache, dribbling of saliva, heaviness of face, taste loss, hyperacusis. Total 30 patients were taken for study. Objective criteria for assessment is incomplete closure of eye. Accurate tests are applied to data. Study reveals that Triphala Ghruta Akshitarpana has effect on only 2 symptoms of Ardita. i.e. Incomplete closure of eye and watering of eye.


2014 ◽  
Vol 4 (5) ◽  
Author(s):  
Mohammed Ather ◽  
, Nasreen ◽  
K V Neelima
Keyword(s):  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Akira Inagaki ◽  
Sachiyo Katsumi ◽  
Shinji Sekiya ◽  
Shingo Murakami

AbstractIn Bell’s palsy, electrodiagnosis by electroneurography (ENoG) is widely used to predict a patient’s prognosis. The therapeutic options for patients with poor prognostic results remain controversial. Here, we investigated whether early intervention with intratympanic steroid therapy (ITST) is an effective treatment for Bell’s palsy patients with poor electrodiagnostic test results (≤ 10% electroneurography value). Patients in the concurrent ITST group (n = 8) received the standard systemic dose of prednisolone (410 mg total) and intratympanic dexamethasone (16.5 mg total) and those in the control group (n = 21) received systemic prednisolone at the standard dose or higher (average dose, 605 ± 27 mg). A year after onset, the recovery rate was higher in the ITST group than in the control group (88% vs 43%, P = 0.044). The average House-Brackmann grade was better in the concurrent ITST group (1.13 ± 0.13 vs 1.71 ± 0.16, P = 0.035). Concurrent ITST improves the facial nerve outcome in patients with poor electroneurography test results, regardless of whether equivalent or lower glucocorticoid doses were administered. This may be ascribed to a neuroprotective effect of ITST due to a higher dose of steroid reaching the lesion due to dexamethasone transfer in the facial nerve.


Sign in / Sign up

Export Citation Format

Share Document